Lyme disease is a recently described human disorder characterized initially by erythema chronicum migrans (ECM) that is often followed by cardiac, neurologic, and/or arthritic complications. ECM was initially described in Europe where treatment with penicillin was effective [1] [2] [3] . Subsequently, it has been reported in the United States that ECM and its associated sequelae may be prevented or ameliorated by treatment with antimicrobials such as penicillin and tetracycline [4, 5] . In 1983, Steere et al. [6] found that tetracycline was superior to penicillin in preventing these sequelae. Until recently, in vitro evaluation of these clinical observations was not possible because the etiologic agent for this disease had not been recovered.
A spirochete referred to here as the Lyme disease spirochete (LDS) has now been isolated [7] [8] [9] [10] [11] [12] . To compare the reported clinical efficacy of antimicrobials with in vitro results and to select additional antimicrobials of potential therapeutic benefit, we tested the efficacy of seven antimicrobials in an in vitro assay against five LDS strains (Table 1) . To ensure the detection of any possible difference in strain-tostrain antimicrobial susceptibility, we selected strains to represent different geographical locations and various hosts because of: (a) the occurrence of Lyme disease or ECM in various areas in the United States and other countries [13] [14] [15] [16] [17] [18] ; (b) the isolation of LDS from Ixodes dammini ticks in the United States [10] [11] [12] and I. ricinis ticks from Switzerland [7] ; and (c) the isolation of LDS from blood, cerebrospinal fluid, and ECM lesions of Lyme disease patients [8, 12] . We report here a brief review of these findings, which are reported in greater detail elsewhere [19] . [20] bIn ug/ml c In serial twofold dilutions tion ranges are listed in Table 2 . Stock solutions (1,056 itg/ml) of each antimicrobial, except rifampin, were prepared, filter-sterilized (pore size of 0.2 A), and stored at -70°C in 5 ml aliquots until ready to use. Rifampin at 528 tg/ml was made fresh before each test and was not filtered. A series of twofold working dilutions was prepared on test day for each of the seven antimicrobials. The dilutions were prepared by the method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) [20] . One-tenth ml of the appropriate working dilution was added to culture tubes (13 x 100, plastic, No. 2027, Falcon, Oxnard, California) containing 6.4 ml of BSK medium. These tubes and growth control tubes (BSK without antimicrobials) were inoculated to a final density of 105 cells per ml with a five-day-old culture of the appropriate LDS strain in BSK medium containing 10' actively growing cells per ml.
549
In testing the effect of BSK medium on antimicrobial activity and for quality control of the antimicrobials during each of the three test runs, S. aureus and S. faecalis, grown on heart infusion agar supplemented with 5 percent defibrinated rabbit blood for 18-20 hours at 33°C in air, were suspended in Mueller-Hinton broth (107 cells per ml) and similarly inoculated into separate sets of tubes containing the appropriately diluted antimicrobals. After 120 hours' incubation in air at 33°C the numbers of motile LDS in test cultures were determined by darkfield microscopy and a Petroff-Hausser bacteria counter. Three counts were taken and averaged for each culture. The least concentration of antimicrobial that had < 101 motile LDS per ml with no noticeable cell sediment was considered the MIC. After 20 hours' incubation in air at 33°C, MICs were determined for S. aureus and S. faecalis. The least concentration of antimicrobial that completely inhibited growth (no turbidity and cell sediment) as determined by the unaided eye was considered the MIC.
RESULTS
In the MIC comparison study our results on media influence showed that MICs for the evaluated antimicrobials were similar and that they were within acceptable tolerances (-1 doubling dilution) of the expected values. Guided by these results and the susceptibility standards recommended by the NCCLS [20] for the antimicrobials tested (Table 2) , we found that all the strains of LDS tested were either susceptible or moderately susceptible to all of the antimicrobials evaluated except rifampin (Table 3) . Of the beta-lactams tested, ampicillin was more active than penicillin G; of the tetracyclines, minocycline was more active than either tetracycline-HCl or doxycycline; and the macrolide erythromycin had the lowest MIC of all the antimicrobials tested. DISCUSSION The fact that penicillin G and tetracycline-HCl were active against LDS in vitro supports the observations of Steere et al. [5, 6] that the therapeutic use of these drugs reduces the duration of ECM and either prevents or ameliorates neurologic, cardiac, or arthritic sequelae. Our data also show that other antimicrobials were more effective than these drugs in inhibiting the growth of LDS, suggesting that differences in efficacy in vivo might be expected from different penicillin or tetracycline preparations.
The reasons for the contrasting results between the high in vitro activity of erythromycin and the poorer efficacy in vivo when compared to penicillin and tetracycline are unclear. Such discrepancies between high in vitro activity and lesser clinical efficacy may be seen with other organisms (e.g., Legionella) [21] . The phenomenon emphasizes that our results provide a guide only to antimicrobials that may be effective in vivo.
